Role of FGFR3 in Urothelial Cell Carcinoma: Biomarker and Potential Therapeutic Target

Overview

Journal World J Urol

Specialty Urology

Date 2007 Oct 4

PMID 17912529

Citations 41

Authors

Margaret A Knowles

Affiliations

Soon will be listed here.

Abstract

Although non-invasive bladder tumours (pTa) are the most common group of bladder tumours at presentation, there has until recently been relatively little information on their molecular biology. Thus it was of great interest when mutations in the FGF receptor 3 (FGFR3) were identified in bladder tumours and it became apparent that these were most common in tumours of low grade and stage. Since the initial description of activating mutations of FGFR3, there have been numerous studies confirming the frequency and spectrum of these mutations in bladder cancers of all grades and stages. Mutation screening techniques have evolved and improved. FGFR3 mutation has been assessed as a predictive biomarker in tumour tissues and as a diagnostic biomarker in urine. Efforts have been made to understand the function of FGFR3 in urothelial and other cells. Although our understanding of FGFR3 function is incomplete, it is already apparent that this may represent an important therapeutic target not only in non-invasive bladder cancer but also in a significant number of invasive tumours. This review summarises the current state of knowledge of this interesting receptor in urothelial carcinoma (UC).

Citing Articles

The roles of FGFR3 and c-MYC in urothelial bladder cancer.

Bogale D Discov Oncol. 2024; 15(1):295.

PMID: 39031286 PMC: 11264706. DOI: 10.1007/s12672-024-01173-z.

Oncogenic alterations in advanced NSCLC: a molecular super-highway.

Friedlaender A, Perol M, Banna G, Parikh K, Addeo A Biomark Res. 2024; 12(1):24.

PMID: 38347643 PMC: 10863183. DOI: 10.1186/s40364-024-00566-0.

Recent Trends in Biosensing and Diagnostic Methods for Novel Cancer Biomarkers.

Rao Bommi J, Kummari S, Lakavath K, Sukumaran R, Panicker L, Marty J Biosensors (Basel). 2023; 13(3).

PMID: 36979610 PMC: 10046866. DOI: 10.3390/bios13030398.

The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.

Kang H, Kim W, Yun S Transl Cancer Res. 2022; 9(10):6609-6623.

PMID: 35117271 PMC: 8798786. DOI: 10.21037/tcr-20-1243.

Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions.

Moon C, Gordon M, Moon D, Reynolds T Int J Mol Sci. 2021; 22(23).

PMID: 34884669 PMC: 8657622. DOI: 10.3390/ijms222312864.

References

Tomlinson D, Hurst C, Knowles M . Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 2007; 26(40):5889-99. PMC: 2443272. DOI: 10.1038/sj.onc.1210399. View

Gravas S, Bosinakou I, Kehayas P, Giannopoulos A . Urinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potential. Urol Int. 2004; 73(2):173-7. DOI: 10.1159/000079700. View

van Oers J, Wild P, Burger M, Denzinger S, Stoehr R, Rosskopf E . FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol. 2007; 52(3):760-8. DOI: 10.1016/j.eururo.2007.01.009. View

Cappellen D, de Oliveira C, Ricol D, de Medina S, BOURDIN J, Sastre-Garau X . Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999; 23(1):18-20. DOI: 10.1038/12615. View

Hoque M, Lee J, Begum S, Yamashita K, Engles J, Schoenberg M . High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Res. 2003; 63(18):5723-6. View

Steiner G, Schoenberg M, Linn J, Mao L, Sidransky D . Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med. 1997; 3(6):621-4. DOI: 10.1038/nm0697-621. View

Sturla L, Merrick A, Burchill S . FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells. Br J Cancer. 2003; 89(7):1276-84. PMC: 2394287. DOI: 10.1038/sj.bjc.6601249. View

Zhang X, Ibrahimi O, Olsen S, Umemori H, Mohammadi M, Ornitz D . Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006; 281(23):15694-700. PMC: 2080618. DOI: 10.1074/jbc.M601252200. View

Ooms E, Anderson W, Alons C, Boon M, Veldhuizen R . Analysis of the performance of pathologists in the grading of bladder tumors. Hum Pathol. 1983; 14(2):140-3. DOI: 10.1016/s0046-8177(83)80242-1. View

10.

Avivi A, Yayon A, Givol D . A novel form of FGF receptor-3 using an alternative exon in the immunoglobulin domain III. FEBS Lett. 1993; 330(3):249-52. DOI: 10.1016/0014-5793(93)80882-u. View

11.

Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh B . Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 1997; 276(5314):955-60. DOI: 10.1126/science.276.5314.955. View

12.

van Oers J, Lurkin I, van Exsel A, Nijsen Y, van Rhijn B, van der Aa M . A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005; 11(21):7743-8. DOI: 10.1158/1078-0432.CCR-05-1045. View

13.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

14.

Adar R, Monsonego-Ornan E, David P, Yayon A . Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. J Bone Miner Res. 2002; 17(5):860-8. DOI: 10.1359/jbmr.2002.17.5.860. View

15.

Jang J, Shin K, Park J . Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001; 61(9):3541-3. View

16.

Botteman M, Pashos C, Redaelli A, Laskin B, Hauser R . The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2004; 21(18):1315-30. DOI: 10.1007/BF03262330. View

17.

Naimi B, Latil A, Berthon P, Cussenot O . No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer. Int J Cancer. 2000; 87(3):455-6. View

18.

Terada M, Shimizu A, Sato N, Miyakaze S, Katayama H . Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs. Mol Cell Biol Res Commun. 2001; 4(6):365-73. DOI: 10.1006/mcbr.2001.0306. View

19.

Sibley K, Stern P, Knowles M . Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene. 2001; 20(32):4416-8. DOI: 10.1038/sj.onc.1204543. View

20.

Sibley K, Cuthbert-Heavens D, Knowles M . Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 2001; 20(6):686-91. DOI: 10.1038/sj.onc.1204110. View